GLP-1 Agonist Therapy Center

Could medication exhibit a much desired side effect with once weekly administration?

New study of normal-weight patients suggests weight reduction, insulin requirements.

Patients who responded to medication had greater improvement in cardiometabolic risk factors.

Quality of life in obese patients with type 2 diabetes improved.

Systemic review, network meta-analysis found treatment resulted in greatest reductions in HbA1c, fasting blood glucose, and body weight.

Safety, efficacy of these new classes of diabetic medication require more detailed investigation.

In this week's Homerun Slides, the philosophy for the reduced need for insulin in type 2 patients and the potential benefits of combining GLP-1-based therapies with insulin.

Study results indicate that risk increased similarly for all glucose lowering agents.

In this week's Homerun Slides, the effectiveness of Lixisenatide when added to basal insulin, and strategies for avoiding or minimizing the GI effects of GLP-1.

This printable chart can be used in your office; it explains the medications approved by the FDA for diabetes treatment and the differences between them.